Savara
142 articles about Savara
-
Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors
12/3/2019
Dr. van Es-Johansson, an expert in orphan drug development, is currently the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance
-
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11/27/2019
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the Company's new Chief Medical Officer, an option to purchase 300,000 shares of the Company's common stock with an exercise price of $1.01 per share,
-
Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer
11/18/2019
FDA Pulmonary, Allergy, and Rheumatology Division Veteran and Researcher Will Oversee the Company’s Medical and Regulatory Strategy
-
Savara to Present at the Stifel 2019 Healthcare Conference
11/12/2019
Savara Inc., an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel.
-
Savara Reports Third Quarter 2019 Financial Results and Provides Business Update
11/7/2019
Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis Program
-
Savara to Report Third Quarter 2019 Financial Results and Provide Business Update
10/31/2019
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report third quarter 2019 financial results and provide a business update on Thursday, November 7, 2019.
-
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
10/2/2019
Savara Inc., an orphan lung disease company, announced the response from a Type C meeting with the U.S. Food and Drug Administration regarding the Molgradex development program for autoimmune pulmonary alveolar proteinosis.
-
Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS
9/18/2019
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that additional data from IMPALA, an ongoing pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)
-
Savara Reports Second Quarter 2019 Financial Results and Provides Business Update
8/8/2019
Savara Inc. reported financial results for the second quarter ending June 30, 2019 and provided a business update.
-
Savara to Report Second Quarter 2019 Financial Results and Provide Business Update
8/1/2019
Shareholders and other interested parties may access the conference call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and request the “Savara Inc.” call.
-
Savara to Present at the 39th Annual Canaccord Genuity Global Growth Conference
7/31/2019
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Operating Officer, Taneli Jouhikainen, will present at the Canaccord Genuity Global Growth Conference on Wednesday, August 7, 2019 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time in the Montreal Room at the Intercontinental in Boston.
-
Clinical Catch-up for June 10-14
6/17/2019
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look. -
Savara to Present at the JMP Securities Life Sciences Conference
6/13/2019
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, and Chief Operating Officer, Taneli Jouhikainen, will present at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time in the Fontainebleau room, The St. Regis, New York.
-
Texas-based Savara tried to put a positive spin on the trial and pointed to positive secondary endpoints but it wasn't enough to please investors.
-
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
6/12/2019
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.
-
Savara Reports First Quarter 2019 Financial Results and Provides Business Update
5/9/2019
Savara Inc. reported financial results for the first quarter ending March 31, 2019 and provided a business update.
-
Savara Announces Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis
5/6/2019
Topline results from the study are expected in June 2019.
-
Savara to Report First Quarter 2019 Financial Results and Provide Business Update
5/2/2019
Savara Inc. announced that the Company will report first quarter 2019 financial results and provide a business update on Thursday, May 9, 2019.
-
BioSpace Movers and Shakers Sept. 24
9/24/2018
Here's a look at who's making moves in the biotech and pharma world this week. -
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...